Commercial Trade Name: Rythmonorm (Note: This brand name is specific to the Greek pharmaceutical market)
Propafenone, similar to flecainide, is a Class Ic antiarrhythmic agent. It is primarily indicated for supraventricular tachycardias, specifically atrial fibrillation, but may also be utilized in the management of ventricular arrhythmias. As a Class Ic antiarrhythmic, its administration is contraindicated in patients with a documented history of myocardial infarction and, by extension, broadly contraindicated in patients presenting with structural heart disease.
Indications
- Administered for the prevention of recurrent atrial fibrillation paroxysms.
- Administered for the acute cardioversion of atrial fibrillation episodes, a clinical practice frequently utilized and widely referred to as the “pill in the pocket” strategy.
Adverse Effects
- May induce dizziness, dysgeusia (taste disturbances), blurred vision, and gastrointestinal disorders.
- Cardiovascular manifestations: Atrioventricular (AV) block, sinus node suppression (particularly in patients with pre-existing sick sinus syndrome), and exacerbation of congestive heart failure.
- Proarrhythmic events may frequently manifest in patients with underlying structural heart disease or latent channelopathies.